Trial Profile
Identification of prediction marker for efficacy of anti-IL-5 antibody and observation of time course of biomarkers in asthma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2021
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Acute asthma; Asthma
- Focus Biomarker; Pharmacodynamics
- Acronyms iPOT-5 study
- 03 May 2021 Status changed from recruiting to completed.
- 26 Dec 2017 New trial record